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Abstract
Improved medical and surgical interventions have increased the longevity of patients 
with congenital heart defects and most such patients live into adulthood. Thrombotic 
and thromboembolic complications constitute a major cause of mortality and morbidity 
in patients with adult congenital heart disease (ACHD). Such events include acute 
coronary syndromes, ischemic stroke (cardioembolic due to thrombus formation in the 
systemic ventricle, secondary to atrial arrhythmias, or due to paradoxical embolism), and 
venous thromboembolism. Some thrombotic phenomena are also specific to patients 
with ACHD, such as those related to Fontan circulation. We provide a succinct overview 
of thrombotic and thromboembolic complications in patients with ACHD, focusing on 
stroke and venous thromboembolic events.
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Thrombosis and thromboembolism are the most common 
etiology for acute coronary syndromes, stroke, and venous 
thromboembolism (VTE) and thereby considered as the 
leading cause of death worldwide [1, 2]. With remarkable 
improvements in medical and surgical care to patients with 
congenital heart disease, many of them now survive into 
adulthood [3]. In fact, the number of patients with adult con-
genital heart disease (ACHD) now exceeds that of the pedi-
atric population. Increased longevity and several biological 
factors (including increased thrombogenicity) [4, 5], patho-
physiological factors (such as increased risk of atrial arrhyth-
mias) [6] and iatrogenic factors (such as Fontan physiology) 
puts this growing population at increased risk of thrombotic 
and thromboembolic complications including VTE, stroke, 
and acute coronary syndromes [7] (Fig 1). Despite com-
monness of these phenomena, and the growing burden of 
ACHD, however, there remains a paucity of data on epidemi-
ology, prognostication and management approach for these 
patients.
The significance of such thrombotic complications also led 
to release of a scientific statement by the American heart as-
sociation (AHA) on thrombosis prevention and treatment 
in patients with congenital heart disease [8]. Although pat-
ent foramen ovale (PFO) with or without precedent stroke 
is an important clinical scenario, we opted to exclude that 
population from the current review. Further, acute coronary 
syndrome in patients with ACHD is an emerging topic with 
potential distinct association with certain syndromes [9]. In 
the current mini-review, we chose to focus on broad aspects 
of thrombosis and thromboembolic risk related to VTE and 
stroke in patients with ACHD. We highlight the areas that re-
quire urgent research attention.
ISCHEMIC STROKE
Acute ischemic stroke, most often of embolic nature, may 
occur in several patient subsets with ACHD [12]. Embolic 
stroke in such patients may have various etiologies including 
thrombus formation and embolization from a dysfunctional 
systemic ventricle, left atrial appendage thrombus formation 
in the setting of atrial fibrillation (AF)/ flutter, or paradoxical 
embolism via a right-to-left shunt.
Figure 1: Major Thrombotic and Thromboembolic Presentations 
in Patients with Adult Congenital Heart Disease
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 Table 1: Select Set of Recommendations From the AHA Scientific Statement on Prevention and Treatment of Thrombosis in Patients
With Congenital Heart Disease a
Setting AHA Recommendation Comment
Congenital Heart Dis-
 ease and AF or Atrial
Flutter
Warfarin therapy is recommended
 NOACs have been empirically used but not formally
tested in randomized trials.
 (We need additional studies to better identify the
 subgroups who are at highest risk of thromboembolic
events.)
Fontan Circulation
Warfarin is recommended if patients have doc-
 umented atrial thrombus, atrial arrhythmia, or a
thromboembolic episode.
 A study of 111 patients with Fontan surgery did not show
 a difference in the rate of thromboembolic events among
 patients randomized to warfarin compared with aspirin
 [10]. A subsequent analysis from the study, however,
 showed that patients achieving target INR, or those
receiving aspirin, had lower thromboembolic events com-
pared with those would had a subtherapeutic INR [11].
 Better risk profiling of these patients and identification of
optimal antithrombotic strategies are required.
a Abbreviations: AF, atrial fibrillation; AHA, American heart association; INR, international normalized ratio; NOAC, non-vitamin K oral 
anticoagulant.
There are subsets of ACHD that are proposed to have an 
elevated risk of thrombosis, including those with cyanotic 
defects. For example, although a prior study of cyanotic pa-
tients had not revealed evidence of clinical stroke in 112 par-
ticipants [13], another study of 162 patients with cyanotic 
congenital heart disease reported cerebrovascular events in 
13.6% of patients [14]. More recently, a study of 98 patients 
with cyanotic congenital heart disease from Sweden reported 
imaging evidence of cerebral infarction in nearly half of par-
ticipants. It is important to note that many of these neurolog-
ic events were diagnosed by imaging and were not associated 
with symptoms or clinical sequelae [15].
Despite the clinical rationale for increased thrombosis risk 
in many ACHD patients, in the absence of large studies spe-
cific to patients with ACHD, the evidence for antithrom-
botic therapy is extrapolated from data in broader cohort 
of patients. Generally, antiplatelets agents are employed for 
secondary prevention in acute cryptogenic stroke while an-
ticoagulation is utilized for treatment of systemic ventricular 
thrombosis or paradoxical embolism from VTE. Of note, 
while anticoagulation is used in the setting of AF/Aflutter for 
patients with ACHD, the CHA2DS2-VASc score has not been 
specifically validated in this population. In one study, among 
patients with ACHD and atrial arrhythmias, congenital heart 
disease complexity, but not the CHA2DS2-VASc score, was 
predictive of subsequent thromboembolic events [16]. As 
such, multicenter research delineating thrombosis risk in the 
setting of AF/Aflutter in the ACHD population is warranted.
VENOUS THROMBOEMBOLISM (VTE)
Patients with ACHD may have specific factors that increase 
the risk of VTE [12]. In addition to thrombophilias that may 
be seen in some subsets of patients with ACHD, VTE risk 
may also be related to limited mobility, particularly in pa-
tients with class III or IV symptoms. Additionally, VTE in 
patients with ACHD could be due to specific hemodynamic 
and flow patterns, such as those with Fontan physiology.
Patients with ACHD and Fontan physiology are a special 
subset, with increased risk of stroke, as well as embolic events 
from the right-sided structures, causing PE [17]. Studies have 
suggested an increased risk of thrombotic events and death in 
patients who do not receive any antithrombotics [18]. Based 
on these, the consensus recommendation is to consider an-
ticoagulation for patients with Fontan physiology, particu-
larly if they have coexisting atrial arrhythmias, a history of 
prior embolic events, or evidence of poor venous flow [17]. 
However, choice of treatment varies across institutions with 
anticoagulation and aspirin both frequently used. While war-
farin is the most frequently employed anticoagulant there is 
emerging data regarding the use of non-vitamin K oral antico-
agulants in the adult Fontan patients [19, 20]. Randomized 
trials are necessary to determine both the choice of agent and 
the appropriate timing of anticoagulation.
CONCLUSIONS
In addition to hemodynamic, arrhythmic, and infectious 
complications, patients with ACHD are at significant risk 
for thrombotic and thromboembolic conditions. Clinicians 
should be mindful of thrombotic complication in patients 
with ACDH and consider appropriate diagnostic and ther-
apeutic approaches. Further research is required to identify 
the highest-risk subgroups, and to test strategies that could 
safely mitigate the thrombotic/thromboembolic risk.
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